CYP19A1 and breast carcinoma: To our knowledge, this follow-up analysis from FAKTION is the first demonstration that the addition of a PI3K/AKT/PTEN pathway inhibitor to endocrine therapy results in significantly longer overall survival in patients with aromatase inhibitor-resistant ER-positive, HER2-negative advanced breast cancer compared with endocrine therapy alone.